“…Unfortunately, in case of Eales’ disease, no documentation of biological drug treatment exists. Biological drugs are currently used for the treatment of vasculitis, such as anti-TNF-alpha agents (infliximab, etanercept, adalimumab, golimumab, and certolizumab), anti-interleukin (IL)-6-receptor antibody (tocilizumab), and anti-CD20 antibody (rituximab) [ 6 , 8 , 9 ]. Even so, we need more research on the use of biological drugs for Eales’ disease, which is aggressive and resistant to medical treatment.…”